Jones Financial Companies Lllp Takes $9.49 Million Position in Twist Bioscience Corporation $TWST

Key Points

• Jones Financial Companies Lllp acquired approximately 224,605 shares of Twist Bioscience Corporation, valued at about $9.49 million, increasing its stake to around 0.37%.
• Analysts have a consensus target price of $49.40 for Twist Bioscience, with most giving the stock a "Moderate Buy" rating.
• The company reported quarterly earnings of ($0.47) EPS, surpassing analysts' expectations by $0.07, and generated $96.06 million in revenue.

Jones Financial Companies Lllp acquired a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 224,605 shares of the company's stock, valued at approximately $9,492,000. Jones Financial Companies Lllp owned 0.37% of Twist Bioscience as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. ARK Investment Management LLC boosted its stake in shares of Twist Bioscience by 11.5% during the first quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock valued at $245,045,000 after purchasing an additional 645,730 shares during the period. Vanguard Group Inc. boosted its stake in shares of Twist Bioscience by 1.0% during the first quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock valued at $230,356,000 after purchasing an additional 60,276 shares during the period. EdgePoint Investment Group Inc. purchased a new stake in Twist Bioscience in the first quarter worth $43,705,000. Nuveen LLC purchased a new stake in Twist Bioscience in the first quarter worth $31,960,000. Finally, American Century Companies Inc. lifted its stake in Twist Bioscience by 0.9% in the first quarter. American Century Companies Inc. now owns 763,406 shares of the company's stock worth $29,971,000 after acquiring an additional 7,054 shares during the period.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 2,265 shares of the firm's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $25.76, for a total transaction of $58,346.40. Following the completion of the transaction, the chief executive officer owned 634,740 shares of the company's stock, valued at approximately $16,350,902.40. This trade represents a 0.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Adam Laponis sold 2,449 shares of the firm's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total value of $93,429.35. Following the transaction, the chief financial officer owned 103,569 shares of the company's stock, valued at $3,951,157.35. The trade was a 2.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,911 shares of company stock valued at $288,159 in the last three months. Insiders own 3.01% of the company's stock.

Twist Bioscience Stock Down 1.2%

Twist Bioscience stock traded down $0.30 on Friday, hitting $25.31. 1,502,508 shares of the stock traded hands, compared to its average volume of 1,300,645. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.53 billion, a P/E ratio of -17.46 and a beta of 2.31. The business's fifty day simple moving average is $30.52 and its 200 day simple moving average is $34.18. Twist Bioscience Corporation has a 1 year low of $24.07 and a 1 year high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.07. The business had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TWST. Evercore ISI set a $46.00 price target on Twist Bioscience in a research note on Monday, August 4th. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Twist Bioscience has an average rating of "Moderate Buy" and a consensus target price of $49.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.